

Tabell 2: Grading of key everolimus-related adverse events based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCE)

Kopiert fra Davies M, Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide

Adverse event	Grade 1	Grade 2	Grade 3	Grade 4
Non-infectious pneumonitis	Asymptomatic	Symptomatic; not interfering with ADL	Severe symptoms; interfering with ADL, oxygen indicated	Life-threatening respiratory compromise; urgent intervention indicated
Infections	None	Localised; local intervention indicated	IV antibiotic, antifungal or antiviral intervention indicated; radiology/operative intervention indicated	Life-threatening consequences, e.g. septic shock, hypotension, acidosis, necrosis
Stomatitis	Minimal; normal diet	Symptomatic, but can eat and swallow; modified diet	Symptomatic; unable to adequately aliment or hydrate orally	Symptoms associated with life-threatening consequences
Metabolic events				
Hypercholesterolaemia, mmol/L	>ULN–7.75 mmol/L	>7.75–10.34 mmol/L	>10.34–12.92 mmol/L	>12.92 mmol/L
Hyperglycaemia, mmol/L	>ULN–8.9 mmol/L	>8.9–13.9 mmol/L	>13.9–27.8 mmol/L	>27.8 mmol/L or acidosis
Hypophosphataemia, mmol/L	<LLN–0.8 mmol/L	<0.8–0.6 mmol/L	<0.6–0.3 mmol/L	<0.3 mmol/L
Hypertriglyceridaemia mmol/L	1.71 mmol/L - 3.42 mmol/L	>3.42 mmol/L - 5.7 mmol/L	>5.7 mmol/L - 11.4 mmol/L	>11.4 mmol/L
Hyperuricaemia, mg/dL (mmol/L)	>ULN–10 (≤ 0.59 without physiologic consequences)		>ULN–10 (≤ 0.59 with physiologic consequences)	>10 (>0.59)
Myelosuppression				
Platelets $\times 10^9$ /L	<LLN–75.0 $\times 10^9$ /L	<75.0–50.0 $\times 10^9$ /L	<50.0–25.0 $\times 10^9$ /L	<25.0 $\times 10^9$ /L
Neutrophils $\times 10^9$ /L	<LLN–1.5 $\times 10^9$ /L	<1.5–1 $\times 10^9$ /L	<1.0–0.5 $\times 10^9$ /L	<0.5/ $\times 10^9$ /L

ADL: activities of daily life, BSA: body surface area, IV: intravenous, LLN: lower limit of normal, ULN: upper limit of normal